Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

BACKGROUND: Certolizumab pegol, a PEGylated tumour necrosis factor (TNF)-inhibitor, improves the clinical signs and symptoms of rheumatoid arthritis (RA) when used in combination with methotrexate or as monotherapy. This study evaluatedthe cost-utility of certolizumab pegol versusTNF-inhibitors plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo-Vega, Álvaro, Villoro, Renata, Blasco, Juan Antonio, Talavera, Pablo, Ferro, Belén, Purcaru, Oana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484891/
https://www.ncbi.nlm.nih.gov/pubmed/26124700
http://dx.doi.org/10.1186/s12962-015-0037-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484891/
https://www.ncbi.nlm.nih.gov/pubmed/26124700
http://dx.doi.org/10.1186/s12962-015-0037-9

Ejemplares similares